Overview

Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)

Status:
Unknown status
Trial end date:
2009-10-01
Target enrollment:
0
Participant gender:
All
Summary
To test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.
Phase:
N/A
Details
Lead Sponsor:
Hospital Authority, Hong Kong
Collaborator:
Hong Kong Nasopharyngeal Cancer Study Group Limited
Treatments:
Fluorouracil
Criteria
Inclusion Criteria:

- Undifferentiated or non-keratinizing carcinoma

- Tumor staged as N2-3

- No evidence of distant metastasis M0

- Performance status:0-2

- Marrow: WBC >= 4 and platelet >= 100

- Renal: creatinine clearance >= 60

- Informed consent

Exclusion Criteria:

- WHO type I squamous cell carcinoma or adenocarcinoma

- Age >= 70

- Palliative intent or tumor extent mandating AP opposing facio-cervical fields

- Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in
situ cervical cancer, or other cancer for which the patient has been disease-free for
5 years

- Previous radiotherapy (except non-melanomatous skin cancers outside the intended RT
treatment volume

- Previous chemotherapy

- Patient is pregnant or lactating